Clinical trial
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or…
NCT01796301 · Amgen, Industry · Completed
Key facts
| NCT number | NCT01796301 |
|---|---|
| Title | An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women |
| Official title | An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy |
| Acronym | STRUCTURE |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | Romozosumab, Teriparatide |
| Enrollment | 436 |
| Start date | Jan 31, 2013 |
| Primary completion | May 14, 2015 |
| Completion | May 14, 2015 |
| First posted | Feb 21, 2013 |
| Last update posted | Nov 29, 2022 |
| Countries | Argentina, Belgium, Canada, Colombia, Czechia, Denmark, Hungary, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: